2026 Annual Meeting | C94 - Neurological Complications of Immune-based Cancer Therapies

Date Monday 04/20/26

Time 07:00 AM - 09:00 AM CDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Sarah F. Wesley, MD, MPH

Topic(s) Neuro-oncology

Learning Objectives Participants should be able to recognize the breadth of neurological complications from cancer immunotherapies, including immune checkpoint inhibitors and immune effector cell therapies, such as CAR T-cell therapy; be able to evaluate and diagnose these conditions appropriately; and demonstrate understanding of current management strategies to optimize outcomes.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice, Quality Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic

Event Timeline
07:00 AM - 07:40 AM CDT	Speaker	Peripheral Nervous System Complications of Immune Checkpoint Inhibitors Amanda C. Guidon, MD, MPH
07:40 AM - 08:20 AM CDT	Speaker	Immune Checkpoint Inhibitor-related Complications in the CNS John Probasco, MD, FAAN
08:20 AM - 09:00 AM CDT	Speaker	Neurological Complications of CAR T-Cell Therapy Sarah F. Wesley, MD, MPH

Faculty Disclosures
Sarah F. Wesley, MD, MPH	Dr. Wesley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wesley has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wesley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG therapeutics.
Amanda C. Guidon, MD, MPH	An immediate family member of Dr. Guidon has received personal compensation for serving as an employee of GE Healthcare. Dr. Guidon has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Guidon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Guidon has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Guidon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. Dr. Guidon has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for McGraw Hill. The institution of Dr. Guidon has received research support from NINDS. The institution of Dr. Guidon has received research support from Biosensics. Dr. Guidon has received publishing royalties from a publication relating to health care. Dr. Guidon has a non-compensated relationship as a Committee Member with Myasthenia Gravis Foundation of America that is relevant to AAN interests or activities.
John Probasco, MD, FAAN	Dr. Probasco has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Journal Watch Neurology. The institution of Dr. Probasco has received research support from Roche/Genentech.

��ɫ��

��ɫ��